Anti-Viral Drug Therapy Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global anti-viral drug therapy market.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Gain a global perspective on the development of the market.
Description:
Where is the largest and fastest growing market for the anti-viral drug therapy market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global anti-viral drug therapy market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by drug class, by application.
- Market Characteristics - The market characteristics section of the report defines and explains the anti-viral drug therapy market. This chapter also defines and describes goods and related services covered in the report.
- Trends And Strategies - This chapter describes the major trends shaping the global anti-viral drug therapy market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the anti-viral drug therapy market.
- Global Market Size And Growth - This section contains the global historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
- Regional Market Size and Growth - This section contains the region’s market size (2019), historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global anti-viral drug therapy market, estimated market shares and company profiles for the leading players.
- Key Mergers And Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Future Outlook and Potential Analysis - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions And Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for anti-viral drug therapy companies in terms of product offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report
Markets Covered:
The global anti-viral drug therapy market is segmented -
- By Drug Class: DNA (Nucleotide) Polymerase Inhibitors; Reverse Transcriptase Inhibitors; Protease Inhibitors; Neuraminidase Inhibitors; Others
- By Application: HIV; Hepatitis; Herpes; Influenza; Others
Companies Mentioned: Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson & Johnson; AbbVie Inc.; Merck & Co., Inc.
Countries: China, Japan, India, Australia, Indonesia, South Korea, USA, Brazil, UK, Germany, France, Russia
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Anti-Viral Drug Therapy Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
6.1.1. Segmentation By Geography
6.1.2. Segmentation By Drug Class
6.1.3. Segmentation By Application
7. Anti-Viral Drug Therapy Market Characteristics
7.1. Market Definition
7.2. Market Segmentation By Drug Class
7.2.1. DNA (Nucleotide) Polymerase Inhibitors
7.2.2. Reverse Transcriptase Inhibitors
7.2.3. Protease Inhibitors
7.2.4. Neuraminidase Inhibitors
7.2.5. Others
7.3. Market Segmentation By Application
7.3.1. HIV
7.3.2. Hepatitis
7.3.3. Herpes
7.3.4. Influenza
7.3.5. Others
8. Anti-Viral Drug Therapy Market Trends And Strategies
8.1. Combination Drug Therapy For Viral Diseases
8.2. Strategic Collaborations And Agreements
8.3. Global Research Initiatives And Funding
8.4. 3D Bioprinting Technology
8.5. Increasing Number Of Pipeline Studies And Drug Development
9. Impact Of COVID-19 On Anti-Viral Drug Therapy Market
9.1. Background
9.2. Drug Therapies
9.3. Antiviral Remdesivir Market Growth
10. Global Anti-Viral Drug Therapy Market Size And Growth
10.1. Market Size
10.2. Historic Market Growth, 2015 - 2019, Value ($ Million)
10.2.1. Drivers Of The Market 2015 - 2019
10.2.2. Restraints On The Market 2015 - 2019
10.3. Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
10.3.1. Drivers Of The Market 2019 - 2023
10.3.2. Restraints On The Market 2019 - 2023
11. Anti-Viral Drug Therapy Market, Regional And Country Analysis
11.1. Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
11.2. Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Billion)
12. Global Anti-Viral Drug Therapy Market Segmentation
12.1. Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
12.2. Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
13. Asia-Pacific Anti-Viral Drug Therapy Market
13.1. Asia Pacific Anti-Viral Drug Therapy Market Overview
13.1.1. Region Information
13.1.2. Market Information
13.1.3. COVID-19 Impact
13.1.4. Background Information
13.1.5. Government Initiatives
13.1.6. Regulations
13.1.7. Regulatory Bodies
13.1.8. Major Associations
13.1.9. Taxes levied
13.1.10. Corporate Tax Structure
13.1.11. Investments
13.1.12. Major Companies
13.2. Asia-Pacific Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
13.3. Asia-Pacific Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
13.4. Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
13.5. Asia-Pacific Anti-Viral Drug Therapy Market: Country Analysis
13.6. China Anti-Viral Drug Therapy Market
13.7. China Anti-Viral Drug Therapy Market Overview
13.7.1. Country Information
13.7.2. Market Information
13.7.3. COVID-19 Impact
13.7.4. Background Information
13.7.5. Government Initiatives
13.7.6. Regulations
13.7.7. Regulatory Bodies
13.7.8. Major Associations
13.7.9. Taxes levied
13.7.10. Corporate Tax Structure
13.7.11. Investments
13.7.12. Major Companies
13.8. China Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
13.9. China Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
13.10. China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
13.11. Australia Anti-Viral Drug Therapy Market
13.12. Australia Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
13.13. Australia Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
13.14. Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
13.15. India Anti-Viral Drug Therapy Market
13.16. India Anti-Viral Drug Therapy Market Overview
13.16.1. Country Information
13.16.2. Market Information
13.16.3. COVID-19 Impact
13.16.4. Background Information
13.16.5. Government Initiatives
13.16.6. Regulations
13.16.7. Regulatory Bodies
13.16.8. Major Associations
13.16.9. Taxes levied
13.16.10. Corporate Tax Structure
13.16.11. Investments
13.16.12. Major Companies
13.17. India Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
13.18. India Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
13.19. India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
13.20. Indonesia Anti-Viral Drug Therapy Market
13.21. Indonesia Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
13.22. Indonesia Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
13.23. Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
13.24. Japan Anti-Viral Drug Therapy Market
13.25. Japan Anti-Viral Drug Therapy Market Overview
13.25.1. Country Information
13.25.2. Market Information
13.25.3. COVID-19 Impact
13.25.4. Background Information
13.25.5. Government Initiatives
13.25.6. Regulations
13.25.7. Regulatory Bodies
13.25.8. Major Associations
13.25.9. Taxes levied
13.25.10. Corporate Tax Structure
13.25.11. Investments
13.25.12. Major Companies
13.26. Japan Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
13.27. Japan Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
13.28. Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
13.29. South Korea Anti-Viral Drug Therapy Market
13.30. South Korea Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
13.31. South Korea Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
13.32. South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
14. Western Europe Anti-Viral Drug Therapy Market
14.1. Western Europe Anti-Viral Drug Therapy Market Overview
14.1.1. Region Information
14.1.2. Market Information
14.1.3. COVID-19 Impact
14.1.4. Background Information
14.1.5. Government Initiatives
14.1.6. Regulations
14.1.7. Regulatory Bodies
14.1.8. Major Associations
14.1.9. Taxes levied
14.1.10. Corporate Tax Structure
14.1.11. Investments
14.1.12. Major Companies
14.2. Western Europe Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
14.3. Western Europe Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
14.4. Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
14.5. Western Europe Anti-Viral Drug Therapy Market: Country Analysis
14.6. UK Anti-Viral Drug Therapy Market
14.7. UK Anti-Viral Drug Therapy Market Overview
14.7.1. Country Information
14.7.2. Market Information
14.7.3. COVID-19 Impact
14.7.4. Background Information
14.7.5. Government Initiatives
14.7.6. Regulations
14.7.7. Regulatory Bodies
14.7.8. Major Associations
14.7.9. Taxes levied
14.7.10. Corporate Tax Structure
14.7.11. Investments
14.7.12. Major Companies
14.8. UK Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
14.9. UK Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
14.10. UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
14.11. France Anti-Viral Drug Therapy Market
14.12. France Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
14.13. France Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
14.14. France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
14.15. Germany Anti-Viral Drug Therapy Market
14.16. Germany Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
14.17. Germany Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
14.18. Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
15. Eastern Europe Anti-Viral Drug Therapy Market
15.1. Eastern Europe Anti-Viral Drug Therapy Market Overview
15.1.1. Region Information
15.1.2. Market Information
15.1.3. COVID-19 Impact
15.1.4. Background Information
15.1.5. Government Initiatives
15.1.6. Regulations
15.1.7. Regulatory Bodies
15.1.8. Tax Levied
15.1.9. Associations
15.1.10. Corporate Tax Structure
15.1.11. Investments
15.1.12. Major Companies
15.2. Eastern Europe Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
15.3. Eastern Europe Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
15.4. Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
15.5. Eastern Europe Anti-Viral Drug Therapy Market: Country Analysis
15.6. Russia Anti-Viral Drug Therapy Market
15.7. Russia Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
15.8. Russia Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
15.9. Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
16. North America Anti-Viral Drug Therapy Market
16.1. North America Anti-Viral Drug Therapy Market Overview
16.1.1. Region Information
16.1.2. Market Information
16.1.3. COVID-19 Impact
16.1.4. Background Information
16.1.5. Government Initiatives
16.1.6. Regulations
16.1.7. Regulatory Bodies
16.1.8. Major Associations
16.1.9. Taxes levied
16.1.10. Corporate Tax Structure
16.1.11. Investments
16.1.12. Major Companies
16.2. North America Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
16.3. North America Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
16.4. North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
16.5. North America Anti-Viral Drug Therapy Market: Country Analysis
16.6. USA Anti-Viral Drug Therapy Market
16.7. USA Anti-Viral Drug Therapy Market Overview
16.7.1. Country Information
16.7.2. Market Information
16.7.3. COVID-19 Impact
16.7.4. Background Information
16.7.5. Government Initiatives
16.7.6. Regulations
16.7.7. Regulatory Bodies
16.7.8. Major Associations
16.7.9. Corporate Tax Structure
16.7.10. Investments
16.7.11. Major Companies
16.8. USA Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
16.9. USA Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
16.10. USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
17. South America Anti-Viral Drug Therapy Market
17.1. South America Anti-viral Drug Therapy Market Overview
17.1.1. Region Information
17.1.2. Market Information
17.1.3. COVID-19 Impact
17.1.4. Background Information
17.1.5. Government Initiatives
17.1.6. Regulations
17.1.7. Regulatory Bodies
17.1.8. Tax Levied
17.1.9. Associations
17.1.10. Corporate Tax Structure
17.1.11. Investments
17.1.12. Major Companies
17.2. South America Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
17.3. South America Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
17.4. South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
17.5. South America Anti-Viral Drug Therapy Market: Country Analysis
17.6. Brazil Anti-Viral Drug Therapy Market
17.7. Brazil Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
17.8. Brazil Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
17.9. Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
18. Middle East Anti-Viral Drug Therapy Market
18.1. Middle East Anti-Viral Drug Therapy Market Overview
18.1.1. Region Information
18.1.2. Market Information
18.1.3. COVID-19 Impact
18.1.4. Background Information
18.1.5. Government Initiatives
18.1.6. Regulations
18.1.7. Major Associations
18.1.8. Taxes Levied
18.1.9. Corporate Tax Structure
18.1.10. Investment
18.1.11. Major Companies
18.2. Middle East Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
18.3. Middle East Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
18.4. Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
19. Africa Anti-Viral Drug Therapy Market
19.1. Africa Anti-Viral Drug Therapy Market Overview
19.1.1. Region Information
19.1.2. Market Information
19.1.3. COVID-19 Impact
19.1.4. Background Information
19.1.5. Government Initiatives
19.1.6. Regulations
19.1.7. Regulatory Bodies
19.1.8. Taxes Levied
19.1.9. Corporate Tax Structure
19.1.10. Investments
19.1.11. Corporate Tax Structure
19.1.12. Major Companies
19.2. Africa Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 - 2019, Value ($ Million)
19.3. Africa Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
19.4. Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
20. Global Anti-Viral Drug Therapy Market Competitive Landscape
20.1. Company Profiles
20.2. Gilead Sciences Inc
20.2.1. Company Overview
20.2.2. Products And Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. GlaxoSmithKline plc
20.3.1. Company Overview
20.3.2. Products And Services
20.3.3. Business Strategy
20.3.4. Financial Overview
20.4. Johnson & Johnson
20.4.1. Company Overview
20.4.2. Products And Services
20.4.3. Business Strategy
20.4.4. Financial Overview
20.5. AbbVie Inc.
20.5.1. Company Overview
20.5.2. Products And Services
20.5.3. Business Strategy
20.5.4. Financial overview
20.6. Merck & Co., Inc.
20.6.1. Company Overview
20.6.2. Products And Services
20.6.3. Business Strategy
20.6.4. Financial Overview
21. Anti-Viral Drug Therapy Market, Key Mergers And Acquisitions
21.1. Merck and Ridgeback Bio Collaborate
21.2. Gilead Acquired Three Antiviral Portfolios From Novartis
21.3. Johnson & Johnson Acquired Novira Therapeutics, Inc.
21.4. Johnson & Johnson Acquired Alios
22. Anti-Viral Drug Therapy Market Future Outlook and Potential Analysis
22.1. Global Anti-Viral Drug Therapy Market In 2023 - Countries Offering Most New Opportunities
22.2. Global Anti-Viral Drug Therapy Market In 2023 - Segments Offering Most New Opportunities
22.3. Global Anti-Viral Drug Therapy Market In 2023 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies
23. Anti-Viral Drug Therapy Market, Conclusions And Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Place
23.2.3. Price
23.2.4. Promotion
23.2.5. People
24. Appendix
24.1. Market Data Sources
24.2. Research Methodology
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
24.6. Copyright And Disclaimer
Samples
LOADING...
Executive Summary
This report describes and evaluates the global anti-viral drug therapy market. It covers 2015 to 2019, termed the historic period, and 2019 to 2023 termed the forecast period, along with further forecasts for the periods 2023-2025 and 2025-2030.
The global anti-viral drug therapy market reached a value of nearly $46,456.4 million in 2019, having increased at a compound annual growth rate (CAGR) of 5.0% since 2015. The market is expected to grow from $46,456.4 million in 2019 to $ 61,571.9 million in 2020 at a rate of 32.5%. The growth is mainly due to the increase in number of COVID-19 cases. The market is then expected to grow at a CAGR of 8.3% from 2021 and reach $74,385.9 million in 2023. The market is expected to reach $ 87,230.5 million in 2025, and $ 130,125.3 million in 2030.
Growth in the historic period resulted from a rise in the incidence of viral diseases, rapid growth in the elderly population and strong economic growth. Factors that negatively affected the growth of the market include patent expiration and increased pricing pressures. Going forward, the rising number of COVID-19 cases and the development of drug discovery procedures will positively affect the market. Factors that could hinder the growth of the anti-viral drug therapy market in the future include COVID-19 pandemic and shortage of supply of anti-viral drugs.
The anti-viral drug therapy market is segmented by drug class into DNA (Nucleotide) polymerase inhibitors, protease inhibitors, reverse transcriptase inhibitors, neuraminidase inhibitors and others. Reverse transcriptase inhibitors market was the largest segment of the anti-viral drug therapy market segmented by drug class, accounting for 50.0% of the total in 2019. Also, it is expected to be the fastest-growing segment in the anti-viral drug therapy market segmented by drug class, at a CAGR of 20.0% during 2019-2023.
The anti-viral drug therapy market is also segmented by application into HIV, hepatitis, herpes, influenza and others. The HIV market was the largest segment of the anti-viral drug therapy market segmented by application, accounting for 34.1% of the total in 2019. Going forward, the influenza segment is expected to be the fastest-growing segment in the anti-viral drug therapy market segmented by application, at a CAGR of 14.5% during 2019-2023.
North America was the largest region in the global anti-viral drug therapy market, accounting for 50.6% of the total in 2019. It was followed by the Asia Pacific and Western Europe, and then the other regions. Going forward, the fastest-growing regions in the anti-viral drug therapy market will be the Asia Pacific and Africa, where growth will be at CAGRs of 14.7% and 13.8% respectively. These will be followed by the Middle East and North America, where the markets are expected to grow at CAGRs of 13.7% and 12.3% respectively.
The global anti-viral drug therapy market is highly concentrated, with a small number of global players in the market. The top ten competitors in the market made up to 76.53% of the total market in 2019. Major players in the market include Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, AbbVie Inc., and Merck & Co., Inc.
The top opportunities in the anti-viral drug therapy market segmented by drug class will arise in the reverse transcriptase inhibitors market segment, which will gain $24,880.4 million of global annual sales by 2023. The top opportunities in the anti-viral drug therapy market segmented by application will arise in the HIV segment, which will gain $ 10,038.8 million of global annual sales by 2023.
The anti-viral drug therapy market size will gain the most in India at $13,190.3 million. Market-trend-based strategies for the anti-viral drug therapy market include developing combination drugs, investing in strategic collaborations, leveraging 3D bioprinting to accelerate process of drug development. Player-adopted strategies in the anti-viral drug therapy market include expanding through strategic acquisitions and collaborations, and launching new drugs and focusing on the development of drugs against COVID-19.
Amidst the unprecedented outbreak of coronavirus, governments across the world are advising people to stay indoors and practice social distancing, to reduce the spread of the pandemic. This has decreased short-term potential growth opportunities for the anti-viral drug therapy industry. Lockdown halted manufacturing activities several countries owing to social distancing measures. However, an increasing number of COVID-19 cases across the world is positively affecting the anti-viral drugs market.
To take advantage of the opportunities, the publisher recommends the anti-viral drug therapy companies to focus on combination drug therapies, invest in 3D bioprinting technology, focus on R&D investments and research collaborations, focus on increasing production temporarily during the covid-19 pandemic, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, provide premium pricing for branded drugs, focus on increasing awareness on the importance of healthcare, advising asthmatics to use preventive medication to protect against covid-19, focus on educating the people on vaccines and focus on developing generics drugs.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Ache
- Alium
- Alkem Laboratories
- Apotex
- Ascedis Health
- Astellas Pharma
- AstraZeneca
- Atea Pharmaceuticals
- Aurobindo Pharma
- BioCryst Pharmaceuticals Inc.
- Biolab Farmaceutica
- BMS
- Boehringer Ingelheim
- Bristol-Myers-Squibb
- ChemRar Group
- China Meheco
- Chugai Pharmaceutical Co.
- Cipla Inc
- Cristalia
- CSPC Pharmaceutical
- Daewoong Pharmaceutical Co.,Ltd
- Daiichi Sankyo
- Divis Laboratories
- Dr. Reddy’s Laboratories Ltd
- Eisai
- Emergent BioSolutions
- EMS Pharma
- Eurofarma
- Fosun Pharma
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals
- Guangzhou Pharmaceutical Company Limited
- Gulf Pharmaceutical Industries (Julphar)
- Hanmi Pharmaceutical
- Harbin Pharmaceutical Group
- Hikma Pharmaceuticals
- Hypermarcas
- Intas Pharmaceuticals
- Jiangsu Hengrui Medicine Co., Ltd
- Johnson & Johnson
- Johnson & Johnson
- KYORIN Holdings, Inc.
- Libbs
- Lupin Limited
- Medical Appliances Corporation (SPIMACO)
- Medley
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma
- Mylan Laboratories
- Nichi-Iko Pharmaceutical Co., Ltd
- Novartis AG
- Novo Nordisk
- Otsuka Pharmaceutical
- Pfizer
- Pharmasyntez
- Pharmstandard
- R-Pharm
- Roche Holding AG
- Sanofi
- Saudi Pharmaceutical Industries
- Selva Therapeutics
- Servier
- Shanghai Acebright Pharmaceuticals Group Co., Ltd.
- Shanghai Pharmaceuticals
- Shionogi Co.Ltd.
- Sinopharm Group
- Strides Pharma
- Sumitomo Dainippon Pharma
- Sun Pharma
- Takeda Pharmaceutical Company
- Teuto Brasileiro
- Teva UK Limited
- União Quimica
- Vectura Group
- Xian-Janssen Pharmaceutical Ltd
- Yangtze River Pharmaceutical Group
- Zydus Cadila
Methodology
LOADING...
